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Introduction {#sec1}
============

The centrosomes are crucial for bipolar spindle formation in human cells. They are composed of the centrioles acting as a core and the surrounding pericentriolar materials from which microtubules are nucleated and organized ([@bib5], [@bib30]). As cells pass through mitosis, the two tightly associated centrioles in one centrosome are disengaged to form two separated centrioles ([@bib1], [@bib2], [@bib4]). They are held together through a proteinaceous linker consisting of a number of proteins, such as rootletin, Cep68, LRRC45, and C-Nap1 ([@bib3], [@bib11], [@bib14], [@bib18]). C-Nap1 is a large coiled-coil protein locating at the proximal end of centrioles and acting as a docking site for the linker proteins such as rootletin and LRRC45 ([@bib18], [@bib39]). This linker persists from G1 till late G2, when it is disassembled and the two linked centrosomes are subsequently disconnected and pulled apart to the opposite poles of the cell by the motor proteins, such as Eg5, for spindle formation in mitosis ([@bib25], [@bib26]).

At the onset of mitosis, NIMA (never in mitosis A)-related kinase Nek2A is the primary kinase responsible for initiating centrosome separation (also called centrosome disjunction) ([@bib26], [@bib37], [@bib38]). It phosphorylates C-Nap1, rootletin, and LRRC45, thereby disassembling the linker to disconnect the centrosomes ([@bib3], [@bib10], [@bib11], [@bib16], [@bib18]). Nek2A itself is also subject to phosphorylation by a hippo pathway component Mst2 at four serine residues including Ser356, Ser365, Ser406, and Ser438 in its non-catalytic C-terminal region ([@bib25]). This in turn accelerates phosphorylated Nek2A to further accumulate at centrosomes. Preventing phosphorylation at these residues by Ala replacement leads to Nek2A incapability to induce premature centrosome separation (also called centrosome splitting) ([@bib25], [@bib23]). Given that the unphosphorylated Nek2A is still able to accumulate at centrosomes, albeit the level being slightly reduced in some cases ([@bib25], [@bib23]), the precise mechanism underlying its incapability to induce centrosome splitting remains uncertain. Nevertheless, the accumulation of phosphorylated, but not unphosphorylated, Nek2A at centrosomes appears to be necessary for centrosome disjunction.

In G2, besides Nek2A, three other mitotic kinases including Cdk1, Plk1, and Aurora A (AurA) are also implicated in centrosome disjunction ([@bib23], [@bib26], [@bib37], [@bib38]). Among them, AurA is mainly responsible for the activation of Plk1 by phosphorylating Thr210 residue in the activation loop of Plk1 ([@bib22], [@bib34]). In this process, binding of CDK1-dependent phosphorylated Bora to Plk1 is pre-required for AurA to access the activation loop ([@bib31]). Plk1 is a serine/threonine kinase that is crucial for centrosome maturation, spindle assembly, microtubule-kinetochore attachment, and cytokinesis ([@bib6]). It localizes at centrosomes and plays pivotal roles in centrosome disjunction at the onset of mitosis by activating Nek2A as well as motor protein Eg5 ([@bib23], [@bib35]). Mst2 is one of its centrosomal targets that is implicated in regulating Nek2A activity. Plk1-dependent phosphorylation of Mst2 at three residues including Ser15, Ser18, and Ser316 locating outside its kinase domain leads to the dissociation of protein phosphatase 1 gamma (PP1γ) from Mst2-Nek2A-PP1γ complex, thereby preventing PP1γ from further dephosphorylating C-Nap1 ([@bib23]). Given that PP1γ does not directly dephosphorylate Nek2A ([@bib23]), and that it has never been detected to localize at centrosomes where Nek2A resides, it is unknown to what extent Plk1 actually contributes to Nek2A activation through this process. The facts that inhibition or depletion of Plk1 leads to cell cycle arrest in a prometaphase-like state with unseparated centrosomes ([@bib20], [@bib23]), and that it is recruited to centrosomes during S, G2, and mitosis and is first activated in G2 ([@bib22], [@bib34]), indicate that Plk1 should play some unidentified roles critical for determining Nek2A activation at centrosomes in late G2.

Recently, we have identified a centrosomal protein Cep85 as another negative regulator for Nek2A ([@bib7]). It can physically interact with and suppress Nek2A kinase activity. The Nek2A-binding domain (NBD), a region within Cep85, has been defined to interact with the non-catalytic C-terminal region of Nek2A ([@bib7]), where four residues that have been identified to be phosphorylated by Mst2 and are essential for Nek2A activation in late G2 reside ([@bib25]). However, the exact mechanism of Nek2A inhibition upon Cep85 binding to its noncatalytic region remains unknown. Importantly, Cep85 co-localizes with Nek2A at the proximal end of centrosomes and also steadily increases its level at centrosomes from G1 to G2. Cep85 depletion leads to centrosome splitting, and overexpression can overcome the effect of Nek2A overexpression, which would otherwise lead to centrosome splitting. Given that it appears at the right time and right place, and acts in the right way, we propose that Cep85 is the primary negative regulator at centrosomes to antagonize Nek2A to maintain the centrosomal integrity in interphase. If it is the case, there should exist a substantial way for Nek2A to overcome Cep85 antagonism to elevate its kinase activity for centrosome disjunction at G2/M transition.

In this study, we have employed a number of biochemical and biological strategies to address the mechanism of Cep85 regulation in late G2 and have revealed a critical role for Plk1 and Nek2A at centrosomes for centrosome disjunction.

Results {#sec2}
=======

Plk1 Interacts with Cep85 {#sec2.1}
-------------------------

To date, it is unclear how Nek2A activity at centrosomes can achieve a threshold level in the presence of a large amount of its antagonist Cep85 at the onset of mitosis. Based on our previous findings showing that Nek2A once co-expressed with Cep85 can induce Cep85 phosphorylation ([@bib7]), we reasoned that Cep85 phosphorylation might affect Cep85-Nek2A affinity. Given that Nek2A is not the kinase directly phosphorylating Cep85 ([@bib7]), we decided to identify the potential kinase. We first co-expressed Cep85 with five kinases that are required for centrosome disjunction including AurA, Cdk1, Mst2, Nek2A, and Plk1, individually, and examined the mobility shift of Cep85. Compared with the control, co-expression of AurA did not lead to the mobility shift of Cep85, Cdk1 displayed a negligible effect, Mst2 exhibited a moderate effect, and Plk1 had a significant effect similar to Nek2A ([Figure 1](#fig1){ref-type="fig"}A). Meanwhile, Cep85 could co-immunoprecipitate with AurA, Cdk1, Plk1, and Nek2, which has been reported previously ([@bib7]). Among them, Plk1 exhibited the highest affinity to Cep85 ([Figure 1](#fig1){ref-type="fig"}B). As Plk1 can strongly bind to and cause a mobility shift of Cep85, we further investigated their interaction in detail. Reciprocal co-immunoprecipitation revealed that Cep85 was also complexed with immunoprecipitated Plk1 ([Figure 1](#fig1){ref-type="fig"}C). In addition, the endogenous Plk1 could be co-immunoprecipitated by the endogenous Cep85 ([Figure 1](#fig1){ref-type="fig"}D). The physical interaction between Cep85 and Plk1 was further confirmed by the reciprocal co-immunoprecipitation of the endogenous proteins ([Figure 1](#fig1){ref-type="fig"}E). Furthermore, *in vitro* GST pull-down assays revealed that insect-cell-produced Plk1 could bind to the recombinant Cep85 protein ([Figure 1](#fig1){ref-type="fig"}F). Consistent with previous reports ([@bib22], [@bib34]), quantitative image analyses revealed that Plk1 first appeared at centrosomes with a low level around early G2 and was steadily increased thereafter ([Figures 1](#fig1){ref-type="fig"}G and 1I). When co-stained with Cep85, Plk1 was readily detected to partially co-localize with Cep85 in early G2, increasingly at G2/M, and extensively from prophase to metaphase ([Figures 1](#fig1){ref-type="fig"}G--1I). These results reveal that Plk1 physically interacts with Cep85 at centrosomes, suggesting that Plk1 could be the kinase phosphorylating Cep85.Figure 1Plk1 Interacts with Cep85(A--C) HEK293T cells were co-transfected with FLAG-Cep85 and hemagglutinin (HA)-tagged kinases. The cell lysates were subjected to immunoblotting (IB) assays to detect the mobility shift of Cep85 (A), or to co-immunoprecipitation assays followed by immunoblotting, to determine the binding affinity of the indicated kinases to Cep85 (B) and the binding affinity of Cep85 to Plk1 (C). TCL, total cell lysates; IP, immunoprecipitation.(D) The endogenous Cep85 was precipitated (IP) from HEK293T cell lysates with anti-Cep85 antibody, and anti-Plk1 antibody was used to detect Plk1 in the precipitates and cell lysates (Input).(E) The endogenous Plk1 was precipitated (IP) from HEK293T cell lysates with anti-Plk1 antibody, and anti-Cep85 antibody was used to detect Cep85 in the precipitates and cell lysates (Input).(F) The interaction of the bacterially produced GST-Cep85 and His-tagged Plk1 purified from insect cells was examined by *in vitro* GST pull-down assays. CBB, Coomassie brilliant blue stain.(G--I) The cell-cycle-dependent co-localization of Cep85 and Plk1 in HeLa cells were revealed by co-immunostaining with anti-Cep85 (red) and anti-Plk1 (green) antibodies. DNA (blue) was stained with DAPI (G). The boxed areas are shown at a higher magnification directly below the corresponding image. Scale bar, 5 μm. The relative fluorescent intensities of Cep85 and Plk1 from 40 cells in individual stages were quantitated and plotted in (H) and (I), respectively. \*p \< 0.05, \*\*\*\*p \< 0.0001.

Plk1 Is the Genuine Kinase to Phosphorylate Cep85 {#sec2.2}
-------------------------------------------------

To verify whether Plk1 is the real kinase phosphorylating Cep85, we first utilized a kinase-dead mutant Plk1-K82M to examine whether this dominant negative mutant could block Nek2A-induced Cep85 mobility shift. Plk1-K82M was confirmed to have lost its capability to phosphorylate Cep85 ([Figure 2](#fig2){ref-type="fig"}A). It could gradually decrease the mobility shift of Cep85 induced by Nek2A in a dosage-dependent manner ([Figure 2](#fig2){ref-type="fig"}B). Conversely, a kinase-dead mutant Nek2A-K37R could not prevent the mobility shift of Cep85 induced by Plk1 even at a high dosage ([Figure 2](#fig2){ref-type="fig"}C). These results thus suggest that Plk1 might act downstream of Nek2A and be the candidate kinase responsible for Nek2A-induced Cep85 phosphorylation. This is further supported by the finding showing that Nek2A-induced Cep85 mobility shift could be suppressed by short hairpin RNA (shRNA)-mediated depletion of the endogenous Plk1 ([Figure 2](#fig2){ref-type="fig"}D). Furthermore, the calf-intestinal alkaline phosphatase treatment assays revealed that the kinase for Cep85 phosphorylation is a serine/threonine kinase ([Figure 2](#fig2){ref-type="fig"}E). To directly demonstrate that Plk1 is the real kinase to phosphorylate Cep85, we performed *in vitro* kinase assays. Among five kinases, only Plk1 could efficiently phosphorylate Cep85 that was expressed in mammalian cells, whereas Mst2 could itself be autophosphorylated ([Figure 2](#fig2){ref-type="fig"}F). We thus conclude that Plk1 is the genuine kinase responsible for Cep85 mobility shift induced by Nek2A in cells, an issue that was raised in our previous report but remained unsolved ([@bib7]).Figure 2Plk1 Is the Genuine Kinase to Phosphorylate Cep85(A) The differential effects of Plk1 proteins on Cep85 mobility shift. FLAG-Cep85 was co-expressed with indicated Plk1 constructs in HEK293T cells, individually. Cep85 phosphorylation was displayed by immunoblotting (IB) to reveal its mobility shift with anti-FLAG antibody and its phosphorylation of Cep85-Thr392 with phospho-antibody anti-pT392 (referring to [Figure 3](#fig3){ref-type="fig"}). TCL, total cell lysates; WT, wild-type; KM, kinase-dead mutant Plk1-K82M; TD, constitutively active mutant Plk1-T210D.(B) Different amounts of kinase-dead mutant HA-Plk1-K82M were co-expressed with FLAG-Cep85 and HA-Nek2A in HEK293T cells. The mobility shift of FLAG-Cep85 was visualized by western blot.(C) Different amounts of the kinase-dead mutant HA-Nek2A-K37R were co-expressed with FLAG-Cep85 and wild-type HA-Plk1 in HEK293T cells. The mobility shift of FLAG-Cep85 was visualized by western blot.(D) HEK293T cells were infected with indicated lentiviral shRNAs 12 hr before co-transfection with FLAG-Cep85 and HA-Nek2A. Cell lysates were prepared 20 hr post-transfection and subjected to immunoblotting.(E) FLAG-Cep85 co-transfected either with active Plk1-T210D or inactive Plk1-K82M in HEK293T cells was immunoprecipitated and subjected to the calf-intestinal alkaline phosphatase (CIP) treatment analysis.(F) FLAG-Cep85 and HA-tagged kinases were immunoprecipitated from HEK293T cell lysates, individually, and subjected to *in vitro* kinase assay with \[γ-^32^P\]-ATP. The phosphorylated proteins were detected by autoradiography.

Plk1 Heavily Phosphorylates the Nek2A-Binding Domain in Cep85 at Centrosomes in Late G2 {#sec2.3}
---------------------------------------------------------------------------------------

To address whether Cep85 phosphorylation could affect Cep85-Nek2A affinity, we decided to identify the phospho-sites in Cep85 first. We initially applied a full-length Cep85 that had been co-expressed with wild-type Plk1 to mass spectrometry. Over 30 serine/threonine residues in Cep85 were identified to be phosphorylated across the whole sequence, but few sites were located in the NBD (amino acid \[aa\] 257--433) defined previously ([@bib7]) (data not shown). This prompted us to modify our approaches for sample preparation by using N-terminal truncated Cep85 (aa 1--543) and a constitutively active mutant Plk1-T210D ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Six residues within the NBD including Ser280, Ser352, Ser361, Thr392, Ser406, and Ser417 were identified to be phosphorylated ([Figure S1](#mmc1){ref-type="supplementary-material"}B, highlighted in red). Among them, a phosphopeptide with the amino acid sequence QREN-pT-FLRAQFAQK around Thr392 was chosen as an antigen for the phospho-specific antibody production.

The produced phospho-antibody against phospho-Thr392 in Cep85 (hereafter referred to as anti-pT392) was first subjected to analysis for its specificity. This phospho-antibody could specifically recognize the Cep85 protein that was co-expressed with Plk1-wild-type (WT) or Plk1-T210D, but not with Plk1-K82M ([Figure 2](#fig2){ref-type="fig"}A). It also could not recognize Cep85-T392A in which Thr392 had been altered to Ala ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, this antibody could recognize a protein at centrosomes with a low signal in G2 but a strong signal in M ([Figures 3](#fig3){ref-type="fig"}B--3D, shGFP). This signal completely disappeared in G2 and remarkably reduced in M after Cep85 was depleted ([Figures 3](#fig3){ref-type="fig"}B--3D, shCep85). The remnant signal in M was likely due to the low levels of Cep85 at centrosomes ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D). All together, these results validate that our anti-pT392 antibody can specifically recognize the phosphorylated Cep85 induced by Plk1. It is noteworthy that Cep85 depletion undoubtedly led to centrosome splitting ([Figures 3](#fig3){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). This is consistent with our previous report and emphasizes the importance of Cep85 in maintaining centrosome integrity in interphase ([@bib7]).Figure 3Plk1 Is Required for Cep85 Phosphorylation(A--D) Validation of the specificity of phospho-antibody anti-pT392. WT and T392A mutant of FLAG-Cep85 were co-expressed with active mutant Plk1-T210D (Plk1-TD) in HEK293T cells. Western blot was employed to detect the phosphorylation of Thr392 residue in Cep85 with anti-pT392 antibody as well as the mobility shift of Cep85 proteins with anti-FLAG antibody (A). (B) HeLa cells were infected with either shGFP (control) or shCep85 lentiviral particles 72 hr before co-immunostaining with anti-γ-tubulin (red) and anti-pT392 (green). The relative fluorescent intensities of γ-tubulin and Cep85pT392 were quantitated and plotted in (C) and (D), respectively. HA, hemagglutinin.(E--G) (E) HeLa cells were fixed and stained with anti-Cep85 antibody for endogenous Cep85 (green) and with anti-pT392 for phosphorylated Cep85 (red). The relative fluorescent intensities of Cep85 and Cep85pT392 were quantitated and plotted in (F) and (G), respectively.(H) HeLa cells were enriched at G1/S using a double thymidine block. After releasing, cells were harvested at indicated time points before western blot analysis with antibodies to detect the endogenous proteins, individually. The levels of Cep85 phosphorylation from one representative experiment were quantitated and shown directly below the western blot with anti-pT392 antibody.(I--L) HeLa cells were synchronized using a double thymidine block. After releasing, cells were further treated either with DMSO (control) or BI2536. They were either harvested at 9 hr post-treatment before immunoblotting (IB) with indicated antibodies to detect phosphorylated Cep85 as well as the endogenous proteins, individually (I), or fixed at 8 hr and 11 hr post-treatment before co-immunostaining with anti-γ-tubulin (red) and anti-pT392 (green) (J). The relative fluorescent intensities of γ-tubulin and Cep85pT392 in (J) were quantitated and plotted in (K) and (L), respectively.(M--P) HeLa cells were infected with the indicated lentiviral shRNAs 20 hr before either western blot analysis (M) or fixation for co-immunostaining with antibodies against γ-tubulin (red) and phospho-Thr392 (green) in (N). The relative fluorescent intensities of γ-tubulin and Cep85pT392 were quantitated and plotted in (O) and (P), respectively. For immunostaining experiments, the boxed areas are shown at a higher magnification directly below the corresponding image. The relative fluorescent intensities of the indicated proteins from 40 cells in each group were quantified.Data are mean ± SEM; ns, not significant; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001. Scale bar, 5 μm. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Next, we examined Cep85 phosphorylation throughout the cell cycle in detail. Consistent with our previous findings ([@bib7]), we observed that Cep85 resided at centrosomes throughout the whole cell cycle and steadily increased its levels from G1 to M phase ([Figures 3](#fig3){ref-type="fig"}E and 3F). In comparison, phosphorylated Cep85 could be detected barely in early G2 but readily at G2/M with a steeply increased level; it reached the maximal level in metaphase ([Figures 3](#fig3){ref-type="fig"}E and 3G). The intensity of Cep85 phosphorylation was increased over 2.5-fold at G2/M and approximately 4-fold in metaphase compared with that in G2 ([Figure 3](#fig3){ref-type="fig"}G). These results revealed that Cep85 is heavily phosphorylated at centrosomes at G2/M.

The pattern of Cep85 phosphorylation shown above is reminiscent of the activity of Plk1 over the cell cycle ([@bib22], [@bib34]). To validate the relationship between Cep85 phosphorylation and Plk1 activity, we synchronized HeLa cells and examined Cep85 phosphorylation over the cell cycle by western blot. The expression patterns of Nek2A and Cyclin B1 validated the synchrony of cell cycle ([Figure 3](#fig3){ref-type="fig"}H). Remarkably, our anti-pT392 phospho-antibody could also recognize the endogenous Cep85 protein detected by immunoblotting ([Figure 3](#fig3){ref-type="fig"}H). The overt Cep85 phosphorylation appeared at 8.5 hr, was increased at 9 and 10 hr, and was greatly reduced at 11 hr onward, whereas Cep85 protein remained unchanged throughout the cell cycle. Plk1 protein was steadily increased from 6 to 10 hr, slightly reduced at 11 hr, and steeply decreased to a basal level thereafter. Its activity, revealed by anti-Plk1pT210, remained high from 8.5 to 11 hr ([Figure 3](#fig3){ref-type="fig"}H). These results indicate that the levels of Cep85 phosphorylation are well correlated with Plk1 activity over the cell cycle.

To further confirm that Plk1 phosphorylates Cep85 *in vivo*, we utilized BI2536 to inhibit Plk1 activity or the shRNA technique to deplete Plk1 in cells before examining the effect of Plk1 inhibition/depletion on Cep85 phosphorylation. Consistent with the above findings ([Figure 3](#fig3){ref-type="fig"}H), Cep85 was heavily phosphorylated at 9 hr after releasing from a double thymidine block ([Figure 3](#fig3){ref-type="fig"}I, DMSO). It, however, was no longer phosphorylated after BI2536 treatment ([Figure 3](#fig3){ref-type="fig"}I, BI2536). The effect of Plk1 inhibition on Cep85 phosphorylation was alternatively confirmed by immunostaining with anti-pT392 antibody after BI2536 treatment, revealing a dramatic decrease of Cep85 phosphorylation and γ-tubulin accumulation at centrosomes ([Figures 3](#fig3){ref-type="fig"}J and 3K). Similar to Plk1 inhibition above, Plk1 depletion also resulted in a significant reduction of Cep85 phosphorylation ([Figures 3](#fig3){ref-type="fig"}N--3P), although it did not alter the overall levels of Cep85 or γ-tubulin ([Figure 3](#fig3){ref-type="fig"}M). These results further confirm that Plk1 is the genuine kinase phosphorylating endogenous Cep85 in cells.

Nek2A Binding but Not Its Kinase Activity Is Pre-required for Cep85 to be Phosphorylated by Plk1 {#sec2.4}
------------------------------------------------------------------------------------------------

Given that Nek2A cannot phosphorylate Cep85 and Plk1 is the real kinase phosphorylating Cep85 ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), it seemed that Nek2A might not be required for Plk1-mediated Cep85 phosphorylation. However, it is not the case. When the endogenous Nek2A was depleted, Plk1 could no longer phosphorylate Cep85 ([Figure 4](#fig4){ref-type="fig"}A), the endogenous Cep85 protein that was heavily phosphorylated in late G2 was not phosphorylated any more ([Figure 4](#fig4){ref-type="fig"}B, 9 hr), and phosphorylated Cep85 at centrosomes was lost in G2 and substantially reduced in M ([Figures 4](#fig4){ref-type="fig"}C--4E). In contrast, Nek2A depletion did not alter the overall level of Cep85 or γ-tubulin ([Figure S3](#mmc1){ref-type="supplementary-material"}). Unlike Plk1 inhibition or depletion, Nek2A depletion had less effect on centrosomal integrity, judged by the higher levels of γ-tubulin retained at centrosomes in the Nek2A-depleted cells ([Figures 4](#fig4){ref-type="fig"}C and 4D) than in the Plk1-inhibited or Plk1-depleted cells ([Figures 3](#fig3){ref-type="fig"}J, 3K, 3N, and 3O).Figure 4Nek2A Binding, but Not Its Kinase Activity, Is Pre-required for Cep85 Phosphorylation by Plk1(A) HEK293T cells were infected with indicated lentiviral shRNAs for 30 hr before co-transfection with FLAG-Cep85 and HA-Plk1. Cell lysates were prepared and subjected to immunoblotting 20 hr post-transfection. HA, hemagglutinin.(B) HeLa cells were infected with indicated lentiviral shRNAs 20 hr before synchronization with a double thymidine block. After releasing, cells were harvested at indicated time points followed by immunoblotting (IB) with indicated antibodies.(C--E) HeLa cells were infected with indicated lentiviral shRNAs for 36 hr before fixation for co-immunostaining with antibodies against γ-tubulin (red) and phosphorylated Cep85-Thr392 (green) (C). The boxed areas in (C) are shown at a higher magnification directly below the corresponding image. The relative fluorescent intensities of γ-tubulin and Cep85pT392 were quantitated and plotted in (D) and (E), respectively. In each group 40 cells were quantified. Data are mean ± SEM; ns, not significant; \*p \< 0.05; \*\*\*\*p \< 0.0001; scale bar, 5 μm.(F) The recombinant GST-Cep85 and immunoprecipitated kinases were subjected to *in vitro* kinase assays with \[γ-^32^P\]-ATP. CBB, Coomassie brilliant blue stain; IB, immunoblotting.(G) The recombinant GST-Cep85 was incubated with HEK293T cell lysates transfected with indicated constructs before *in vitro* kinase assays with \[γ-^32^P\]-ATP. The mobility shift of Cep85 was visualized by CBB staining after prolonged separation (p.s.) of samples on an SDS-PAGE.(H) GST-Cep85 was pre-bound with either active Nek2A-WT or kinase-dead Nek2A-K37R before *in vitro* kinase assays in the presence of either active Plk1-T210D (Plk1-TD) or inactive Plk1-K83M (Plk1-KM). After reaction, the samples were washed to remove unbound proteins before immunoblotting. Prolonged separation followed by CBB staining or western blot with anti-pT392 antibody was used to reveal phosphorylated Cep85. Western blot with anti-HA antibody was applied to detected Nek2A proteins remaining on Cep85 after the kinase reaction. The amount of retained Nek2A was quantitated and plotted in the lower panel. Data are mean ± SEM from three independent experiments, \*\*\*\*p \< 0.0001.(I) Schematic diagram of Nek2A deletion mutants are shown in the upper panel. GST-Cep85 was preincubated with cell lysates containing WT, N terminus (N), or C terminus (C) of Nek2A before *in vitro* kinase assays, followed by similar treatments as mentioned in (H). The intensity of Cep85pT392 and the amount of Nek2A proteins that remained on GST-Cep85 were quantitated and are shown below the representative western blots, respectively.See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

To find out the mechanism by which Nek2A is required for Cep85 phosphorylation, we carried out *in vitro* kinase assays by using bacterially produced GST-Cep85 instead of mammalian-cell-expressed Cep85, which had been shown to be an excellent substrate for Plk1 ([Figure 2](#fig2){ref-type="fig"}F). To our surprise, GST-Cep85 could not be phosphorylated by any kinases, whereas the autophosphorylation of Mst2 kinase was again readily detected ([Figure 4](#fig4){ref-type="fig"}F). We reasoned that something was missing from bacterially produced GST-Cep85. It is indeed the case. After pre-incubating GST-Cep85 with FLAG-Nek2A to form a Cep85-Nek2A complex, Plk1 again could phosphorylate GST-Cep85 ([Figure 4](#fig4){ref-type="fig"}G). Remarkably, phosphorylated GST-Cep85 could be readily recognized due to a prominent mobility shift after prolonged separation (p.s.) of the samples in SDS-PAGE ([Figure 4](#fig4){ref-type="fig"}G, CBB p.s.). Importantly, this provides us a simpler approach to examine Cep85 phosphorylation than autoradiography *in vitro*.

To determine the contribution of Nek2A kinase activity to Cep85 phosphorylation, we applied additional kinase-dead mutants including Nek2A-K37R and Plk1-K82M to the same assays. As expected, Plk1-T210D could efficiently phosphorylate GST-Cep85 complexing with wild-type Nek2A, judged by the overt mobility shift of GST-Cep85 and immunoblotting with anti-pT392 antibody ([Figure 4](#fig4){ref-type="fig"}H, lane 6). Intriguingly, kinase-dead mutant Nek2A-K37R was still able to promote Cep85 phosphorylation to an almost same level, indicating that binding, but not kinase activity, of Nek2A is pre-required for Cep85 to be phosphorylated by Plk1 ([Figure 4](#fig4){ref-type="fig"}H, lane 13). In contrast, Plk1-K82M could not phosphorylate Cep85 even in the presence of Nek2A-WT ([Figure 4](#fig4){ref-type="fig"}H, lanes 7 and 14), indicating that Plk1 kinase activity is necessary. To determine the amount of Nek2A that remained on Cep85 after it was phosphorylated by Plk1, we had modified the *in vitro* kinase assays by incorporating an additional wash step to remove unbound proteins before denaturing the samples. Importantly, we found that the amount of Nek2A that remained on Cep85 was greatly reduced and that less that 40% of either wild-type or mutant Nek2A was retained on Cep85 ([Figure 4](#fig4){ref-type="fig"}H, lanes 6 and 13), indicating that Cep85 phosphorylation may diminish the binding affinity of phospho-Cep85 to Nek2A that was expressed in mammalian cells.

Our previous study has demonstrated that Nek2A binds to Cep85 via its C-terminal region, but not its N-terminal region containing the kinase domain ([@bib7]). To further confirm that Nek2A binding, but not its kinase activity, is critical for Cep85 phosphorylation, we decided to determine whether binding of the C-terminal region of Nek2A is sufficient for Cep85 phosphorylation. *In vitro* GST pull-down assays confirmed that GST-Cep85 could bind to full-length and C-terminal region of Nek2A ([Figure S4](#mmc1){ref-type="supplementary-material"}). *In vitro* kinase assays revealed that the C-terminal region of Nek2A could still boost Cep85 phosphorylation, albeit at a less efficiency than the full-length one, but the N-terminal region could not promote Cep85 phosphorylation, which was likely due to its incapability to interact with Cep85 ([Figures 4](#fig4){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}). Consistently, the binding affinity of phosphorylated Cep85 to either full-length or C-terminal Nek2A was significantly reduced and appeared to be inversely proportional to the degree of Cep85 phosphorylation ([Figure 4](#fig4){ref-type="fig"}I). All together, these results reveal that binding, but not the kinase activity, of Nek2A is pre-required for Cep85 to be phosphorylate by Plk1.

Binding of Plk1 to Cep85 Does Not Preclude Nek2A from Cep85-Nek2A Complex, and They Can Further Form a Ternary Plk1-Cep85-Nek2A Complex {#sec2.5}
---------------------------------------------------------------------------------------------------------------------------------------

As both Nek2A and Plk1 can bind to Cep85, we initially hypothesized that there might exist certain types of competition that would eventually lead to the dissociation of Nek2A-Cep85. To test this possibility, we first would like to fine-map the region in Cep85 binding to Plk1. A series of Myc-tagged Cep85 truncated mutants were generated and were co-expressed with HA-Plk1 in HEK293T cells, and co-immunoprecipitation assays were performed ([Figure 5](#fig5){ref-type="fig"}A). We observed that the first 33 aas in Cep85 were not required for Plk1 binding, but that further truncated mutants from the N terminus including M2-5 gradually decreased their binding affinity to Plk1, suggesting that aa 34--188 is required for Cep85 to interact with Plk1 ([Figures 5](#fig5){ref-type="fig"}A and 5B). However, M6 containing aa 1--256 alone completely lost its binding affinity to Plk1, suggesting that aa 34--188 is not sufficient for Cep85 to bind to Plk1. We thus further extended their length gradually toward the Cep85 C terminus. The binding affinity of these extended truncated mutants including M7-9 were gradually recovered and reached a plateau when it was extended to residue 433 (M10) ([Figures 5](#fig5){ref-type="fig"}A and 5B). Therefore the Plk1-binding region is located in Cep85 N-terminal region aa 34--433. In fact, a mutant consisting of aa 34--174 and aa 285--433 largely retained its binding affinity, indicating that Plk1 simultaneously binds to Cep85 in two regions, one around aa 34--187 and the other around aa 257--433.Figure 5Binding of Plk1 to Cep85 Does Not Preclude Nek2A from Cep85-Nek2A Complex, and They Can Form a Ternary Plk1-Cep85-Nek2A Complex(A and B) Plk1 simultaneously interacts with two small regions in the N-terminal region of Cep85. A schematic diagram of Cep85 and its truncated mutants are shown in (A). The numbers indicate the positions of the first or the last amino acid of individual fragments. The relative binding affinity of the truncated mutants to Plk1 is shown on the left. +++, highest binding affinity to Plk1; -, no binding affinity to Plk1. Myc-Cep85 and its truncated mutants were co-expressed with HA-Plk1 in HEK293T cells followed by co-immunoprecipitation (IP) and immunoblotting (IB) (B) TCL, total cell lysates.(C) Nek2A binding does not interfere with the interaction of Cep85 and Plk1. Cep85, Plk1-K83M (KM), and different amounts of Nek2A-K37R (KR) were co-expressed in HEK293T cells before co-immunoprecipitation and immunoblotting.(D) Cep85, Plk1, and Nek2A form a ternary complex in mammalian cells. The procedure of the experiment is outlined in the upper panel, and western blot analysis after two-step immunoprecipitation is shown in the lower panel.(E) Nek2A depletion does not alter the binding affinity of endogenous Plk1 and Cep85. HEK 293T cells were infected with indicated lentiviral shRNAs before co-immunoprecipitation and immunoblotting with indicated antibodies 48 hr post-infection.(F) Plk1 inhibition might elevate the binding affinity of endogenous Nek2A and Cep85 in late G2. HeLa cells were synchronized with a double thymidine block. Five hours after releasing, cells were treated with BI2536 for additional 4 hr before co-immunoprecipitation and immunoblotting with indicated antibodies. The binding affinity of Nek2A to Cep85 was quantitated by comparing the amount of Nek2A in the immunoprecipitate (IP) with that in the input, and the results are shown below the representative western blot from three independent experiments.

Given that the NBD (aa 257--433) partially overlaps with Plk1-binding regions ([Figure 5](#fig5){ref-type="fig"}A), we were curious to test whether binding of Cep85 to Plk1 and Nek2A were mutually exclusive. To rule out any potential unexpected effects of the kinase activity on their interaction, we chose kinase-dead mutants of Plk1 and Nek2 to perform co-immunoprecipitation assays. Plk1-K82M could specifically interact with Cep85 ([Figure 5](#fig5){ref-type="fig"}C). Nek2A-K37R supplemented did not alter the binding affinity of Cep85 and Plk1-K82M even at a high dosage, but rather bound to Cep85 in the same immunoprecipitate ([Figure 5](#fig5){ref-type="fig"}C), suggesting that their interaction is not mutually exclusive. In fact, they can form a ternary Plk1-Cep85-Nek2A complex revealed by a two-step immunoprecipitation assay ([Figure 5](#fig5){ref-type="fig"}D).

To evaluate the contribution of Nek2A to the interaction between Plk1 and Cep85, we carried out co-immunoprecipitation assays to examine the binding affinity of endogenous Plk1 to Cep85 in the presence or absence of Nek2A. We found that Nek2A depletion did not alter the affinity of endogenous Plk1 and Cep85 ([Figure 5](#fig5){ref-type="fig"}E). We further examined whether Plk1 activity would affect the binding affinity of Nek2A and Cep85. When harvesting cells at 9-hr time point after releasing, the binding affinity of endogenous Nek2A and Cep85 might be slightly increased upon BI2536 treatment to inhibit Plk1 activity compared with DMSO treatment in cells ([Figure 5](#fig5){ref-type="fig"}F). This result suggests that Plk1 kinase activity may be required for regulating the binding affinity of Cep85 and Nek2A in late G2.

Nek2A-Assisting Cep85 Phosphorylation by Plk1 Leads to the Dissociation of Phospho-Nek2A from Cep85-Nek2A Complex and Its Activation in Late G2 {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------------------------------

Given that Plk1 binding to Cep85 does not simply preclude Nek2A from Cep85-Nek2A complex ([Figures 5](#fig5){ref-type="fig"}C and 5D), Plk1 activity might affect the binding affinity between Nek2A and Cep85 ([Figures 4](#fig4){ref-type="fig"}H, 4I, and [5](#fig5){ref-type="fig"}F), and both Cep85 and Nek2A can be phosphorylated in late G2 ([@bib25]) ([Figure 3](#fig3){ref-type="fig"}); we thus would like to examine whether phosphorylated Cep85 would alter its binding affinity to phosphorylated Nek2A. We first generated phospho-mimicking mutant Nek2A-4D as well as nonphosphorylatable mutant Nek2A-4A ([Figure 6](#fig6){ref-type="fig"}A) according to the previous report ([@bib25]) and carried out *in vitro* GST pull-down assays to evaluate their binding affinity to the bacterially produced GST-Cep85, which is not supposed to be phosphorylated. Their binding affinity to unphosphorylated GST-Cep85 was indistinguishable ([Figure S5](#mmc1){ref-type="supplementary-material"}A). These Cep85-Nek2A complexes were further subjected to *in vitro* kinase assays. All Nek2A proteins could facilitate Cep85 phosphorylation demonstrated by a distinct mobility shift in the presence of Plk1 and ATP. Among them, Nek2A-4A might be less efficient, revealed by anti-pT392 antibody ([Figure 6](#fig6){ref-type="fig"}B). Similar to those shown above ([Figure 4](#fig4){ref-type="fig"}H), phosphorylated Cep85 significantly reduced its affinity to Nek2A-WT and Nek2A-K37R with approximately 50% Nek2A proteins remaining on Cep85. In contrast, Nek2A-4A largely retained its affinity to phosphorylated Cep85. Remarkably, only about 20% of Nek2A-4D still remained on phosphorylated Cep85 ([Figure 6](#fig6){ref-type="fig"}B). These results indicate that Nek2A-assisting Cep85 phosphorylation by Plk1 will eventually lead to the dissociation of mammalian-cell-expressed Nek2A proteins except for the nonphosphorylatable mutant from the Cep85-Nek2A complex.Figure 6Nek2A-Assisting Cep85 Phosphorylation by Plk1 Leads to the Dissociation of Phospho-Nek2A from Cep85-Nek2A Complex and Its Activation in Late G2(A) Schematic diagram of Nek2A-4D mutant with four phosphorylation sites in Cep85-binding domain mutated to aspartic acid residue.(B) The recombinant GST-Cep85 was incubated with HEK293T cell lysates containing HA-Nek2A proteins before *in vitro* kinase assays. After reaction, the samples were washed to remove unbound proteins before immunoblotting. The relative binding affinity was quantitated by comparing the amount of retained Nek2A in reactions with ATP with that without ATP and is shown below the western blot.(C) Schematic diagram of Cep85-6D mutant with six phosphorylation sites in the Nek2A-binding domain mutated to the acidic residues.(D) FLAG-Cep85 and HA-Nek2A constructs were co-transfected into HEK293T cells as indicated. The binding affinity of Nek2A to Cep85, shown in the upper panel, was quantitated by comparing the amount of Nek2A in the immunoprecipitate (IP) with that in the total cell lysates (TCL).(E and F) (E) GST pull-down assays were performed to evaluate the binding affinity of the recombinant GST-Cep85 proteins to HA-Nek2A proteins overexpressed in HEK293T cells. The binding affinity of Nek2A to GST-Cep85 was quantitated by comparing the amount of Nek2A retained on GST-Cep85 with that in the input and is shown in (F).(G) The effects of Cep85 mutants on the activity of individual Nek2A kinases were determined by *in vitro* kinase assays with \[γ-^32^P\]-ATP. The intensities of autoradiograph bands from three independent experiments were quantified by densitometry and normalized to WT. The relative kinase activity was assessed and is shown in the upper panel.(H) HeLa cells were synchronized using a double thymidine block. After releasing, cells were harvested at indicated time points before immunoprecipitation of endogenous Cep85 and western blotting (IB) to detect Nek2A in the precipitates (IP) and total cell lysates (TCL). The binding affinity of Nek2A to Cep85 was quantitated by comparing the amount of Nek2A in the immunoprecipitate (IP) with that in TCL and is shown in the upper panel.For quantitation analysis, data are mean ± SEM from three independent experiments. ns, not significant; \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

As Plk1 can bulkily phosphorylate Cep85 at multiple sites across the whole protein sequence ([Figure S1](#mmc1){ref-type="supplementary-material"}), we decided to examine whether the phospho-sites within the NBD were sufficient to regulate its binding affinity to Nek2A. We thus altered all six phosphoserine/threonine residues within this domain to create a phospho-mimicking mutant Cep85-6D and a nonphosphorylatable mutant Cep85-6A ([Figure 6](#fig6){ref-type="fig"}C). *In vitro* kinase assays revealed that Ala replacement could slightly reduce Cep85-6A phosphorylation ([Figure S5](#mmc1){ref-type="supplementary-material"}B). They were first subjected to co-immunoprecipitation assays to assess their binding affinity to Nek2A proteins ([Figure 6](#fig6){ref-type="fig"}D). Nek2A-4A largely preserved its affinity to Cep85 proteins regardless of their phosphorylation. In contrast, Nek2A-WT and Nek2A-4D significantly reduced their affinity to Cep85 proteins, in particular, Cep85-WT and Cep85-6D. Compared with the Nek2A-4A, Nek2A-WT displayed about 50% reduction of their affinity to Cep85-WT and Cep85-6D, and Nek2A-4D displayed over 60% reduction ([Figure 6](#fig6){ref-type="fig"}D). It is noteworthy that co-expression of Nek2A-WT or Nek2A-4D, but not Nek2A-4A, resulted in a significant mobility shift of all Cep85 proteins ([Figure 6](#fig6){ref-type="fig"}D, TCL). Nek2A-WT and Nek2A-4D, but not Nek2A-4A, also displayed a mobility shift. These findings suggest that Cep85-WT and Nek2A-WT are indeed phosphorylated in mammalian cells after they are co-expressed. Therefore the reduction of binding affinity between Cep85-WT and Nek2A-WT is still likely attributed to the electrostatic repulsion between them.

To rule out any unexpected effects on Cep85 when it was co-expressed with Nek2A in mammalian cells, we carried out *in vitro* GST pull-down assays to assess their binding affinity by using recombinant GST-Cep85 proteins, which are not considered to be phosphorylated ([Figures 6](#fig6){ref-type="fig"}E and 6F). We found that Nek2A-4A exhibited nearly equal binding affinity to all GST-Cep85 proteins. GST-Cep85-WT and GST-Cep85-6A fully retained their binding affinity to Nek2A-WT and NekA-4D. In contrast, GST-Cep85-6D partially lost its binding affinity to Nek2A-WT and significantly to Nek2A-4D. This discrepancy of their affinity between Nek2A-WT and Nek2A-4D to Cep85-6D may simply be due to the incomplete phosphorylation of Nek2A-WT when it was expressed in mammalian cells.

To address the effect of Cep85 phosphorylation on Nek2A kinase activity, we carried out *in vitro* kinase assays. Similar to our previous report ([@bib7]), the purified Nek2A-WT from insect cells could specifically phosphorylate β-casein, an artificial Nek2A substrate, and bacterially produced GST-Cep85-WT could efficiently inhibit Nek2A kinase activity ([Figure S5](#mmc1){ref-type="supplementary-material"}C). As a negative control, the kinase-dead mutant Nek2A-K37R lost its capability to phosphorylate β-casein, whereas Nek2A-4A largely retained its kinase activity ([Figure 6](#fig6){ref-type="fig"}G). In addition, Nek2A-4D displayed a higher kinase activity with about 40% increase compared with Nek2A-WT or Nek2A-4A; however, the exact mechanism is unclear at present. Compared with the GST control, which was shown to have a negligible effect on the activity of Nek2A proteins, supplementation with GST-Cep85 proteins including WT and 6A led to a significant inhibition of the kinase activity of all Nek2A proteins ([Figure 6](#fig6){ref-type="fig"}G). As expected, GST-Cep85-6D protein also efficiently inhibited Nek2A-WT and Nek2A-4A activities. It, however, significantly lost its capability to suppress Nek2A-4D activity. Under this condition, approximately 70% of Nek2A-4D kinase activity was still retained ([Figure 6](#fig6){ref-type="fig"}G), indicating that Cep85 once is phosphorylated will lose its capability to inhibit phospho-Nek2A kinase activity.

Given that both Cep85 and Nek2A are phosphorylated in cells in late G2 ([@bib25]) ([Figure 3](#fig3){ref-type="fig"}), we would expect to see that the binding affinity of endogenous Cep85 to Nek2A is significantly decreased at that stage. We thus synchronized cells and found that the protein levels of Nek2A were steadily increased from G1/S to late G2 (0--9 hr), whereas Cep85 levels remained unchanged at all time points ([Figure 6](#fig6){ref-type="fig"}H). The patterns of Cyclin B1 confirmed the efficiency of cell synchronization. Importantly, we found that although Cep85 strongly bound to Nek2A in S phase (3- and 6-hr time point), their binding affinity was significantly decreased with only approximately 20% of Nek2A remaining on Cep85 in late G2 (9-hr time point). Collectively, these *in vitro* and *in vivo* data reveal that phosphorylation of Cep85 by Plk1 will result in the dissociation of phospho-Nek2A from the Cep85-Nek2A complex, thereby tremendously elevating the kinase of phospho-Nek2A in late G2.

Cep85 Phosphorylation Is Critical for Centrosome Disjunction {#sec2.7}
------------------------------------------------------------

Centrosome disjunction is initiated by Nek2A-mediated separation of centrosomes at G2/M and is promoted by the motor protein Eg5-dependent pushing force for the spindle formation in mitosis ([@bib25]). Therefore to study the contribution of Nek2A to centrosome separation, we have to inhibit Eg5 activity. Eg5 Inhibition causes cells to arrest at prometaphase with separated centrosomes ([@bib25], [@bib23]). Given that Cep85 phosphorylation diminished its capability to inhibit phospho-Nek2A kinase activity ([Figure 6](#fig6){ref-type="fig"}), we decided to examine the contribution of Plk1-mediated Cep85 phosphorylation to the initiation of centrosome disjunction in cells. A series of GFP fusion Cep85 constructs were generated and expressed in a nearly identical level in HeLa cells to evaluate their roles in centrosome disjunction ([Figures 7](#fig7){ref-type="fig"}A and 7E). These GFP-Cep85 proteins were able to localize at centrosomes ([Figure 7](#fig7){ref-type="fig"}B). When treated with S-trityl-L-cystein (STLC), an inhibitor for Eg5, around 72% of GFP-expressing control cells arrest at prometaphase with a pair of separated centrosomes ([Figures 7](#fig7){ref-type="fig"}A--7D). Cep85-WT when overexpressed could significantly suppress centrosome separation, and Cep85-6A further inhibited centrosome separation. In contrast, Cep85-6D lost its capability to prevent centrosome separation ([Figures 7](#fig7){ref-type="fig"}A--7D). Therefore to ensure centrosome disjunction, Cep85 has to be phosphorylated by Plk1 at least in its NBD.Figure 7Cep85 Phosphorylation Is Critical for Centrosome Disjunction(A--E) The effects of overexpressed Cep85 proteins on centrosome disjunction. (A) Schematic outline of experiments in (B--E). HeLa cells were enriched at G1/S by a double thymidine block before overexpressing GFP as a control (NSC, non-specific control) or indicated GFP-Cep85 proteins. STLC was used to trap cells in the prometaphase before analysis. (B) The transfected cells were fixed and stained with γ-tubulin (red) to indicate centrosomes. The boxed areas are shown at a higher magnification on the right. The distance between two centrosomes (n = 40), percentage of cells with separated centrosomes (n = 120 from three independent experiments), and expression levels of individual proteins in (B) are shown in (C), (D), and (E), respectively.(F--J) The effects of Cep85 proteins on centrosome splitting resulted from Cep85 depletion. (F) Schematic outline of experiments in (G--J). HeLa cells were infected with indicated lentiviral shRNAs before synchronization with a double thymidine block. Co-transfection with indicated plasmids was performed 4 hr before second release, and analysis was performed 8 hr after releasing. (G) The transfected cells were fixed and stained with antibodies to detect Cep85 (green), γ-tubulin (red), and rootletin (magenta). DNA was stained with DAPI (blue). The boxed areas are shown at a higher magnification on the right. The percentage of cells with separated centrosomes (n = 300 from three independent experiments), relative fluorescent intensity of rootletin (n = 40), and expression levels of the endogenous and Myc-tagged Cep85 proteins are shown in (H), (I), and (J), respectively.(K and L) The experiments were performed exactly according to the schematic outline in (F) with two additional time points (6 and 9 hr). Co-immunostaining and the percentage of cells with separated centrosomes (n = 300 from three independent experiments) are shown in (K) and (L), respectively.For immunostaining, centrosomes are considered separated when the distance between them exceeded 2 μm; Data are mean ± SEM; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001; scale bar, 5 μm.

To rule out the potential interference of the endogenous Cep85, we employed shRNA technique to deplete the endogenous Cep85 before overexpressing Cep85 proteins and examining their effects on centrosome separation in interphase ([Figure 7](#fig7){ref-type="fig"}F). Consistent with the previous report ([@bib7]) and the data shown above ([Figure S2](#mmc1){ref-type="supplementary-material"}), Cep85 depletion resulted in the premature separation of centrosomes with reduced levels of the centrosomal linker protein rootletin ([Figure 7](#fig7){ref-type="fig"}G, vector). Expressing siRNA-resistant wild-type Cep85 (SR-WT) or nonphosphorylatable mutant SR-6A largely reversed the effects of Cep85 depletion, displaying the re-connected centrosomes with significantly enhanced rootletin intensity. In contrast, the phospho-mimicking mutant SR-6D partially lost its capability to suppress centrosome splitting under this condition ([Figures 7](#fig7){ref-type="fig"}F--7J). We also notice that the capability of SR-6D to prevent centrosome splitting was highly dependent on the timing of analysis. It efficiently suppressed the centrosome splitting at 6 hr, but partially lost its capability at 8 hr and significantly lost at 9 hr after releasing from a double thymidine block ([Figures 7](#fig7){ref-type="fig"}F, 7K, and 7L). Given that Nek2A can be phosphorylated by Mst2 and Mst2 has been shown to steadily increase its kinase activity from early G2 ([@bib25]), we believe that there might exist a reverse correlation between the capability of phospho-Cep85 to suppress centrosome splitting and the levels of phosphorylated Nek2A in interphase cells.

Both Nek2A and Cep85 Are Required to be Phosphorylated to Ensure Centrosome Separation {#sec2.8}
--------------------------------------------------------------------------------------

To confirm that the capability of phospho-Nek2A to initiate the centrosome disjunction is in fact dependent on the levels of Cep85 phosphorylation, we decided to examine the capability of Cep85 proteins to suppress the centrosome splitting induced by overexpressing phospho-mimicking mutant Nek2A-4D ([Figure 8](#fig8){ref-type="fig"}A). We thus first co-expressed GFP as a non-specific control with Nek2A mutants and found that Nek2A-4D, but not Nek2A-4A, could induce centrosome splitting in interphase ([Figures 8](#fig8){ref-type="fig"}B--8E). This result is consistent with previous reports ([@bib25]). When expressed at an identical level, none of Cep85 proteins including Cep85-6D could alter the centrosome cohesion in cells overexpressing Nek2A-4A. However, both Cep85-WT and Cep85-6A could significantly inhibit Nek2A-4D-induced centrosome splitting ([Figures 8](#fig8){ref-type="fig"}A--8E). In contrast, Cep85-6D significantly lost its capability to suppress the centrosome splitting induced by Nek2A-4D ([Figures 8](#fig8){ref-type="fig"}A--8E). It is noteworthy that Nek2A-4A in all cases resided at centrosomes ([Figure 8](#fig8){ref-type="fig"}B), once again suggesting that in addition to its localization at centrosomes, Nek2A phosphorylation is also critical for centrosome disjunction. These results suggest that to ensure timely initiation of centrosome separation, both Nek2A and Cep85 have to be phosphorylated in late G2.Figure 8Both Nek2A and Cep85 Are Required to be Phosphorylated to Ensure Centrosome Separation(A--E) (A) Schematic outline of experiments in (B--E). HeLa cells were synchronized with a double thymidine block, and co-transfection with indicated plasmids was performed 3 hr before second release, followed by analysis 7 hr after releasing. (B) The transfected cells were fixed and stained with anti-HA antibody to visualize overexpressed HA-Nek2A proteins (red). The boxed areas are shown at a higher magnification on the right. (C) The expression levels of GFP and GFP-Cep85 as well as HA-Nek2A proteins in HeLa cells were examined by western blot. (D) The distance between two centrosomes for cells in (B). n = 120 from three independent experiments. (E) The histogram indicates the percentage of cell with nonseparated centrosomes. n = 240 from three independent experiments. Centrosomes are considered separated when the distance between them exceeded 2 μm. Data are mean ± SEM; scale bar, 5 μm. HA, hemagglutinin.(F) Model for centrosome disjunction regulated by Cep85. At early to mid G2 phase, Cep85 binds to and inhibits Nek2A at centrosomes, thereby preventing Nek2A from phosphorylating intercentrosomal linker consisting of proteins such as C-Nap1 and rootletin. Centrosomes, therefore, remain coherent. As cell cycle progresses into late G2, Cep85 initially still binds to Nek2A regardless of Nek2A phosphorylation, whereas the levels of Nek2A and its phosphorylation mediated by Mst2 kinase at centrosomes are elevated. As Plk1 increases its accumulation at centrosomes and binds to Cep85 to form a ternary complex with Cep85-Nek2A, Cep85 is phosphorylated by Plk1. This leads to the dissociation of phospho-Nek2A exclusively from phosphorylated Cep85 in the complex. Freed phospho-Nek2A initiates centrosome separation by phosphorylating and disassembling the linker between two centrosomes.

Discussion {#sec3}
==========

In this study, we have uncovered a previously unrecognized function of Plk1 and Nek2A for Nek2A activation and provided a model to describe this process in centrosome disjunction ([Figure 8](#fig8){ref-type="fig"}F). According to our study, it is clear that to achieve a threshold activity at G2/M transition, Nek2A must be phosphorylated. Thereby, once Plk1 binds to Cep85 in Cep85-Nek2A complex, it will phosphorylate Cep85. This in turn leads to the dissociation of phospho-Nek2A from phosphorylated Cep85. Eventually, the freed phospho-Nek2A that is no longer inhibited by Cep85 will initiate centrosome disjunction at G2/M transition. In addition, our study has identified Cep85 as the missing piece to directly relay Plk1 activity to Nek2A for its activation in the mitotic kinase cascades for timely centrosome separation, and has provided further mechanistic insight into the long-standing issue regarding the stringent requirement of phosphorylated Nek2A for centrosome disjunction at G2/M.

It is well known that overactive Nek2A can cause centrosome splitting ([@bib10], [@bib12]). As Nek2A protein is steadily increased from S to G2 ([@bib15], [@bib17]), its localized activity at centrosomes must be strictly regulated to keep centrosome unseparated in interphase. To date, several proteins have been reported to antagonize Nek2A. These proteins include protein phosphatase 1 PP1α and pp1γ ([@bib28], [@bib29]), the focal adhesion scaffolding protein HEF1 ([@bib32]), pericentrin ([@bib27]), and Cep85([@bib7]). However, it is unclear to what extent they contribute to the inhibition of Nek2A activity in interphase and how their antagonism is compromised for centrosome disjunction in late G2 except for PP1γ. Plk1-mediated phosphorylation of Mst2 leads to the dissociation of PP1γ from Mst2-Nek2A-PP1γ complex and activation of Nek2A in late G2 ([@bib23]). Given that PP1γ was not found to dephosphorylate Nek2A and there are no available data showing that it localizes at centrosomes wherein significant amount of Nek2A resides and functions, we speculate that this might be not the major way for Nek2A to achieve a threshold activity at G2/M transition.

In our previous studies, we have characterized a centrosomal protein Cep85 as a negative regulator to antagonize Nek2A for maintaining the centrosome integrity in interphase ([@bib7]). In this study, we have followed up our study to address their interaction in late G2. In the mechanistic study, we were initially surprised to see that Plk1 cannot phosphorylate the recombinant Cep85 protein ([Figure 4](#fig4){ref-type="fig"}F). It becomes reasonable when we realized the facts that Nek2A indeed is complexed with Cep85 at centrosomes in cells and Nek2A binding is pre-required for Cep85 to be phosphorylated by Plk1 ([Figure 4](#fig4){ref-type="fig"}) ([@bib7]). The facts that both Cep85 and Nek2A are phosphorylated in late G2 and Nek2A is actively involved in Cep85 phosphorylation for its own activation highly suggest that Cep85 is a primary antagonist for Nek2A in interphase that has to be overcome in late G2 ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}) ([@bib25]). Recently, Cep85 has also been found to bind to STIL to regulate Plk4 activation during centriole duplication ([@bib21]). The interaction of Cep85 and STIL seems to be transient and occurs in the early phase of centriole duplication. It would be interesting to examine whether this portion of Cep85 plays a role by transferring from STIL to Nek2A to prevent premature centrosome separation once it accomplishes its mission during centriole duplication. This hypothesis could be examined by determining Cep85 localization at centrosomes with high resolution after the G1/S transition.

In interphase, the centrosomes are held together by a proteinaceous linker consisting of a number of proteins, such as C-Nap1 and rootletin, and are disjoined by Nek2A-mediated phosphorylation of these linker proteins in late G2 ([@bib3], [@bib16], [@bib26]). Recent studies have revealed a highly regulated kinase cascade CDK1-AurA-Plk1-Nek2A to ensure the timely centrosome separation ([@bib8], [@bib38]). In this cascade, Plk1 is not reported to activate Nek2A directly but to increase Nek2A activity indirectly by phosphorylating the kinase Mst2, a component of the hippo pathway ([@bib23]). Plk1-dependent phosphorylation of Mst2 results in the dissociation of PP1γ from the Mst2-Nek2A-PP1γ complex, thereby preventing PP1γ from dephosphorylating c-Nap1 and indirectly increasing Nek2A activity. It is well known that phosphorylation of Thr180 within the activation loop of Mst2 is crucial for its activation ([@bib9], [@bib13]). Given that Plk1-mediated phosphorylation of Mst2 occurs at three additional sites other than this critical residue, it remains obscure whether Plk1-induced Mst2 phosphorylation also leads to an increase in Mst2 kinase activity that is responsible for Nek2A phosphorylation in late G2 ([@bib25], [@bib23]). Overall, these studies seem to favor the idea that Plk1 can activate Nek2A in an indirect manner.

In our current study, we have provided several lines of evidence to support the argument that Plk1 can indeed directly activate Nek2A through Cep85 in late G2. We have shown that Plk1 can bind to Cep85 and form a ternary Plk1-Cep85-Nek2A complex ([Figures 1](#fig1){ref-type="fig"} and [5](#fig5){ref-type="fig"}). Both Plk1 and Nek2A are required for Cep85 phosphorylation *in vitro* and *in vivo* ([Figures 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}). Nek2A is actively involved in Plk1-mediated Cep85 phosphorylation by converting Cep85 to an excellent substrate for Plk1 by forming a Cep85-Nek2A complex ([Figure 4](#fig4){ref-type="fig"}). In addition, Nek2A-assisting Cep85 phosphorylation leads to the dissociation of phospho-Nek2A from Cep85-Nek2A antagonizing complex and the activation of freed phospho-Nek2A ([Figure 6](#fig6){ref-type="fig"}). It thus becomes clear that to overcome Cep85 antagonism at G2/M transition, Nek2A must first increase its accumulation at centrosomes and then has to be phosphorylated, which is mediated by Mst2 ([@bib25]), although it remains unknown how exactly Mst2 is activated in late G2 ([@bib19]). It also becomes clear that Plk1 at centrosomes plays pivotal regulatory roles in the initiation of centrosome disjunction by activating phospho-Nek2A directly by phosphorylating Cep85 and indirectly by inhibiting PP1γ.

In summary, our results identify Cep85 as a platform to directly relay the activities of Plk1 and Mst2 to Nek2A activation at centrosomes through phospho-Nek2A-assistant Cep85 phosphorylation by Plk1 at the onset of mitosis.

Limitations of the Study {#sec3.1}
------------------------

In this study we have clearly demonstrated that both Plk1 and Nek2A are necessary for Cep85 phosphorylation *in vitro* and *in vivo*. However, we have not yet examined whether they are sufficient for Cep85 phosphorylation because of the lack of the bacterially expressed recombinant Plk1 and Nek2A proteins. We thus do not know whether other centrosome-residing proteins, such as Mst2, are also involved in this process. It would be helpful to further clarify the events that occurred at the G2/M transition during centrosome disjunction if we could solve the problem in our future study.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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